Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 1—January 2012
Research

High Prevalence of Multidrug-Resistant Tuberculosis, Swaziland, 2009–2010

Elisabeth Sanchez-PadillaComments to Author , Themba Dlamini, Alexandra Ascorra, Sabine Rüsch-Gerdes, Zerihun Demissie Tefera, Philippe Calain, Roberto de la Tour, Frauke Jochims, Elvira Richter, and Maryline Bonnet
Author affiliations: Epicentre, Paris, France (E. Sanchez-Padilla, A. Ascorra, M. Bonnet); National Tuberculosis Control Programme, Mbabane, Swaziland (T. Dlamini); National Reference Center for Mycobacteria, Borstel, Germany (S. Rüsch-Gerdes, E. Richter); Médecins Sans Frontières, Geneva, Switzerland (Z.D. Tefera, P. Calain, R. de la Tour, F. Jochims)

Main Article

Table 3

Patterns of second-line drug resistance in rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates, Swaziland, 2009–2010*

Resistance pattern No. (%) isolates resistant to isoniazid or rifampin,† n = 60 No. (%) isolates from case-patients with MDR TB, n = 122
No resistance to second-line drugs 54 (90.0) 72 (49.2)
Any resistance 6 (10.0) 62 (50.8)
  Ethionamide 6 (10.0) 58 (47.5)
  Ofloxacin 0 10 (8.2)
  p-aminosalicylic acid 0 0
  Cycloserine 0 0
  Amikacin 0 2 (1.6)
  Capreomycin 0 3 (2.5)
Specific resistance patterns
  Ethionamide 6 (10.0) 50 (41.0)
  Ethionamide + ofloxacin 0 6 (4.9)
  Ethionamide + amikacin + capreomycin 0 1 (0.8)
  Ethionamide + ofloxacin + amikacin + capreomycin 0 1 (0.8)
  Ofloxacin 0 3 (2.5)
  Capreomycin 0 1 (0.8)
XDR 0 1 (0.8)

*MDR, multidrug resistant; TB, tuberculosis; XDR, extensively drug resistant.
†Isolates from MDR TB patients excluded.

Main Article

Page created: December 16, 2011
Page updated: December 16, 2011
Page reviewed: December 16, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external